ne. Although the vast majority of cases of leukopenia have not progressed to the more serious conditions of aplastic anemia or agranulocytosis, complete pretreatment hematological testing should be obtained as a baseline. If a patient, in the course of treatment, exhibits low or decreased white blood cell or platelet count, the patient should be monitored closely. Patients should be monitored and discontinuation of the drug should be considered if any evidence of bone marrow depression occurs. Carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds. Because the possibility of a suicide attempt is inherent in bipolar disorder, close supervision of high-risk patients should accompany drug therapy.

Notes to editors
APA Poster # 309: Tuesday, May 24, 2005, 12:00 PM ET Georgia World Congress Center, Level 3, Rooms B302-B305 Efficacy of Switching to Carbamazepine Extended-Release Capsules in Bipolar Disorder Richard H. Weisler, MD; Robert Hirschfeld, MD; Thomas Gazda, MD; Terrence A. Ketter, MD; Paul E. Keck, Jr, MD; Alan Swann, MD; and Amir Kalali, MD.

Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company's website: www.shire.com.

'"/>


25-May-2005

Page: 1 2 3
Related medicine news :

1. Traditional Chinese exercises may increase efficacy of flu vaccine
2. International studies show high efficacy for HPV vaccine
3. 12-month study demonstrated tolerability and efficacy of Daytrana
4. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
5. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
6. Studies led by Rhode Island Hospital confirm safety and efficacy
7. Malaria treatment efficacy compromised in certain HIV-positive patients
8. Treating obesity may improve the efficacy of therapy for hepatitis C
9. Four-year data suggest the CYPHER stent provides long-term efficacy and safety benefits
10. FDA expands indication for ADDERALL XR (CII) confirming safety and efficacy in adolescents
11. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients